Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma
Condition(s):Cholangiocarcinoma, IntrahepaticLast Updated:March 4, 2024Recruiting
Include Studies Not Open or Pending
Condition(s):Cholangiocarcinoma, IntrahepaticLast Updated:March 4, 2024Recruiting
Condition(s):Intrahepatic CholangiocarcinomaLast Updated:November 9, 2022Recruiting
Condition(s):Intrahepatic CholangiocarcinomaLast Updated:September 10, 2022Not yet recruiting
Condition(s):CholangiocarcinomaLast Updated:February 10, 2023Recruiting
Condition(s):Intrahepatic CholangiocarcinomaLast Updated:April 13, 2023Recruiting
Condition(s):Intrahepatic CholangiocarcinomaLast Updated:August 5, 2022Recruiting
Condition(s):Cholangiocarcinoma Non-resectableLast Updated:September 26, 2023Recruiting
Condition(s):Intrahepatic Cholangiocarcinoma by AJCC V8 StageLast Updated:June 4, 2020Recruiting
Condition(s):Intrahepatic CholangiocarcinomaLast Updated:February 23, 2022Recruiting
Condition(s):Cholangiocarcinoma With IDH1 Mutation; Solid Tumors With IDH1 MutationLast Updated:December 14, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.